Suppr超能文献

游离/总前列腺特异性抗原比值能否在前列腺活检前预测Gleason评分？

Can the Free/Total PSA Ratio Predict the Gleason Score Before Prostate Biopsy?

作者信息

Ceylan Cavit, Gazel Eymen, Keleş İbrahim, Doluoğlu Ömer, Yığman Metin

机构信息

Department of Urology, Turkey Yüksek İhtisas Training and Research Hospital, Ankara, Turkey.

Department of Urology, Kocatepe University of Medicine, Afyon, Turkey.

出版信息

Curr Urol. 2016 Feb;9(1):24-7. doi: 10.1159/000442846. Epub 2016 Feb 10.

DOI:10.1159/000442846
PMID:26989367
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4789969/
Abstract

OBJECTIVES

To determine whether there is a correlation between high Gleason score and free/total (f/t) prostate specific antigen (PSA) in patients newly diagnosed with prostate carcinoma.

MATERIALS AND METHODS

The study included 272 prostate biopsy patients whose total PSA value ranged from 4-10 ng/ml. The patients were divided into 2 groups according to the f/t PSA ratio: Group 1 ≤ 15% and Group 2 > 15%. Furthermore, the groups were also compared to each other in terms of mild (≤ 6), moderate (= 7), and high (≥ 8) Gleason score.

RESULTS

Group 1 consisted of 135 (49.6%) patients and Group 2 consisted of 137 (50.4%) patients. While 27 (20%) patients had a high Gleason score in Group 1, only 10 (7.3%) patients had a high Gleason score in Group 2 (p = 0.008). Using Spearman's correlation test, we found that the f/t PSA ratios were observed to decrease significantly in all patients with increased Gleason scores (p = 0.002, r = -0.185).

CONCLUSION

According to our study, there is a relationship between higher Gleason score and decreased f/t PSA ratio. Therefore, f/t PSA can be an indicator for predicting the Gleason score.

摘要

目的

确定新诊断的前列腺癌患者中高Gleason评分与游离/总（f/t）前列腺特异性抗原（PSA）之间是否存在相关性。

材料与方法

该研究纳入了272例前列腺活检患者，其总PSA值范围为4 - 10 ng/ml。根据f/t PSA比值将患者分为两组：第1组≤15%，第2组>15%。此外，还对两组患者在低（≤6）、中（=7）和高（≥8）Gleason评分方面进行了比较。

结果

第1组有135例（49.6%）患者，第2组有137例（50.4%）患者。第1组中有27例（20%）患者Gleason评分高，而第2组中只有10例（7.3%）患者Gleason评分高（p = 0.008）。使用Spearman相关性检验，我们发现所有患者的Gleason评分升高时，f/t PSA比值均显著降低（p = 0.002，r = -0.185）。

结论

根据我们的研究，较高的Gleason评分与降低的f/t PSA比值之间存在关联。因此，f/t PSA可作为预测Gleason评分的一个指标。

相似文献

1
Can the Free/Total PSA Ratio Predict the Gleason Score Before Prostate Biopsy?游离/总前列腺特异性抗原比值能否在前列腺活检前预测Gleason评分？
Curr Urol. 2016 Feb;9(1):24-7. doi: 10.1159/000442846. Epub 2016 Feb 10.
2
Free/total PSA ratio can help in the prediction of high gleason score prostate cancer in men with total serum prostate specific antigen (PSA) of 3-10 ng/ml.游离/总前列腺特异性抗原比值有助于预测总血清前列腺特异性抗原（PSA）为3至10 ng/ml的男性中高格里森评分前列腺癌。
Int Urol Nephrol. 2006;38(3-4):553-7. doi: 10.1007/s11255-006-6672-5.
3
The value of free and total prostate specific antigen in identifying patients for prostatic biopsy and its relationship to Gleason score and number of positive cores.游离和总前列腺特异性抗原在前列腺活检患者识别中的价值及其与Gleason评分和阳性核心数量的关系。
J Med Liban. 2000 Mar-Apr;48(2):59-62.
4
Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.在总前列腺特异性抗原水平为2至4纳克/毫升范围内的游离前列腺特异性抗原百分比，与4至10纳克/毫升范围内相比，并不会显著增加检测临床显著性前列腺癌所需的活检次数。
J Urol. 2002 Aug;168(2):504-8.
5
The impact of the biopsy Gleason score on PSA outcome for prostate cancer patients with PSA < or = 10 ng/ml and T1c,2a: implications for patient selection for prostate-only therapy.活检Gleason评分对前列腺特异性抗原（PSA）≤10 ng/ml且处于T1c、2a期的前列腺癌患者PSA转归的影响：对仅接受前列腺治疗的患者选择的意义
Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):847-51. doi: 10.1016/s0360-3016(99)00290-4.
6
The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.前列腺特异性抗原（PSA）密度预测初始前列腺活检和前列腺切除术中 Gleason 评分升级的能力随着肿瘤分级的增加而降低，这是由于单位肿瘤体积的 PSA 分泌减少所致。
BJU Int. 2012 Jul;110(1):36-42. doi: 10.1111/j.1464-410X.2011.10681.x. Epub 2011 Nov 15.
7
Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.前列腺临床器官局限性癌永久性组织间近距离放疗后活检阳性率与生化结果的关系。
Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):664-73. doi: 10.1016/s0360-3016(01)02670-0.
8
Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients.基于活检 Gleason 评分和 PSA 的早期前列腺癌患者的病理性升级或局部进展风险：现代患者的基于人群研究。
Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):244-51. doi: 10.1016/j.ijrobp.2015.01.051. Epub 2015 Apr 1.
9
Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen.使用癌组织活检百分比、活检Gleason分级和血清前列腺特异性抗原预测根治性前列腺切除术后前列腺特异性抗原复发的术前模型。
J Urol. 2004 Jun;171(6 Pt 1):2215-20. doi: 10.1097/01.ju.0000124463.13319.0a.
10
Utility of preoperative serum prostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer.术前血清前列腺特异性抗原浓度和活检 Gleason 评分在预测前列腺癌盆腔淋巴结转移风险中的作用。
Urology. 1994 Oct;44(4):519-24. doi: 10.1016/s0090-4295(94)80050-2.

引用本文的文献

1
The efficacy of prostate health index (PHI) in predicting pathological progression in low-risk localized prostate cancer cases under active surveillance protocol.前列腺健康指数（PHI）在主动监测方案下预测低风险局限性前列腺癌病例病理进展中的效能。
World J Urol. 2025 Jul 12;43(1):431. doi: 10.1007/s00345-025-05820-0.
2
Diagnosis of Prostate Cancer in Patients with Prostate-Specific Antigen (PSA) in the Gray Area: Construction of 2 Predictive Models.前列腺特异性抗原（PSA）灰区患者前列腺癌的诊断：2 种预测模型的构建。
Med Sci Monit. 2021 Feb 8;27:e929913. doi: 10.12659/MSM.929913.
3
Clinical factors affecting prostate-specific antigen levels in prostate cancer patients undergoing radical prostatectomy: a retrospective study.影响接受根治性前列腺切除术的前列腺癌患者前列腺特异性抗原水平的临床因素：一项回顾性研究。
Future Sci OA. 2021 Jan 12;7(3):FSO643. doi: 10.2144/fsoa-2020-0154.
4
Characterisation of the main PSA glycoforms in aggressive prostate cancer.鉴定侵袭性前列腺癌中 PSA 的主要糖型。
Sci Rep. 2020 Nov 4;10(1):18974. doi: 10.1038/s41598-020-75526-3.
5
Establishment of two new predictive models for prostate cancer to determine whether to require prostate biopsy when the PSA level is in the diagnostic gray zone (4-10 ng ml).建立两个新的前列腺癌预测模型，以确定在 PSA 水平处于诊断灰区（4-10ng/ml）时是否需要进行前列腺活检。
Asian J Androl. 2020 Mar-Apr;22(2):213-216. doi: 10.4103/aja.aja_46_19.
6
Expression of ERG Protein and TMRPSS2-ERG Fusion in Prostatic Carcinoma in Egyptian Patients.埃及患者前列腺癌中ERG蛋白表达及TMRPSS2-ERG融合情况
Open Access Maced J Med Sci. 2017 Mar 20;5(2):147-154. doi: 10.3889/oamjms.2017.037. eCollection 2017 Apr 15.

本文引用的文献

1
Cancer statistics, 2014.癌症统计数据，2014 年。
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29. doi: 10.3322/caac.21208. Epub 2014 Jan 7.
2
EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013.EAU 前列腺癌指南。第 1 部分：筛查、诊断和以治愈为目的的局部治疗——2013 年更新。
Eur Urol. 2014 Jan;65(1):124-37. doi: 10.1016/j.eururo.2013.09.046. Epub 2013 Oct 6.
3
Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory.自1988年以来26个欧洲国家五种常见癌症的发病率近期趋势：欧洲癌症观测站分析
Eur J Cancer. 2015 Jun;51(9):1164-87. doi: 10.1016/j.ejca.2013.09.002. Epub 2013 Oct 8.
4
Detection rates and biologic significance of prostate cancer with PSA less than 4.0 ng/mL: observation and clinical implications from Tyrol screening project.前列腺特异性抗原（PSA）低于4.0 ng/mL的前列腺癌的检出率及生物学意义：蒂罗尔筛查项目的观察结果及临床启示
Urology. 2005 Nov;66(5):1029-33. doi: 10.1016/j.urology.2005.05.025.
5
Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.使用人组织激肽释放酶2和前列腺特异性抗原联合临床分期及Gleason分级对病理器官局限型临床T1c期前列腺癌预测准确性的比较
J Urol. 2005 Mar;173(3):752-6. doi: 10.1097/01.ju.0000152618.38747.dd.
6
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.前列腺特异性抗原水平≤4.0纳克/毫升的男性中前列腺癌的患病率。
N Engl J Med. 2004 May 27;350(22):2239-46. doi: 10.1056/NEJMoa031918.
7
Limited usefulness of the free-to-total prostate-specific antigen ratio for the diagnosis and staging of prostate cancer in Japanese men.游离前列腺特异性抗原与总前列腺特异性抗原比值在日本男性前列腺癌诊断和分期中的应用价值有限。
Int J Clin Oncol. 2004 Feb;9(1):64-7. doi: 10.1007/s10147-003-0365-1.
8
Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).游离前列腺特异性抗原与总前列腺特异性抗原比值作为非器官局限性前列腺癌（pT3期）的预测指标
Scand J Urol Nephrol. 2003;37(6):466-70. doi: 10.1080/00365590310001746.
9
The free-to-total serum prostatic specific antigen ratio as a predictor of the pathological features of prostate cancer.游离前列腺特异性抗原与总前列腺特异性抗原比值作为前列腺癌病理特征的预测指标。
Int Urol Nephrol. 2002;34(4):519-23. doi: 10.1023/a:1025685718493.
10
Free/total PSA ratio is a powerful predictor of future prostate cancer morbidity in men with initial PSA levels of 4.1 to 10.0 ng/mL.游离/总前列腺特异性抗原比值是初始前列腺特异性抗原水平为4.1至10.0纳克/毫升的男性未来前列腺癌发病率的有力预测指标。
Urology. 2003 Apr;61(4):760-4. doi: 10.1016/s0090-4295(02)02427-5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验